Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL XX SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
8.7 OTHERS (PRE-CLINICAL AND RESEARCH)
9 MARKET OVERVIEW
9.1 DRIVERS
9.2 RESTRAINTS
9.3 OPPORTUNITIES
9.4 CHALLENGES
10 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , BY PRODUCT
10.1 OVERVIEW
10.2 EQUIPMENTS
10.2.1 BY TYPE
10.2.1.1. HANDHELD
10.2.1.2. FIXED
10.2.1.3. MOBILES
10.2.2 BY MODALITY
10.2.2.1. AUTOMATED
10.2.2.2. MANUAL
10.2.3 BY PRODUCT
10.2.3.1. ANALYSERS
10.2.3.1.1. IMMUNOASSAY ANALYZERS
10.2.3.1.2. BREATH ANALYZERS
10.2.3.2. CHROMATOGRAPHIC DEVICES
10.2.3.3. RAPID TESTING DEVICES
10.2.3.3.1. URINE TESTING DEVICES
10.2.3.3.2. ORAL FLUID TESTING DEVICES
10.2.3.4. OTHERS
10.3 CONSUMABLES
10.3.1 RAPID TEST KITS
10.3.1.1. STRIPS
10.3.1.1.1. MARKET VALUE (USD MILLION)
10.3.1.1.2. MARKET VOLUME (UNITS)
10.3.1.1.3. AVERAGE SELLING PRICE (USD)
10.3.1.2. CASSETTES
10.3.1.2.1. MARKET VALUE (USD MILLION)
10.3.1.2.2. MARKET VOLUME (UNITS)
10.3.1.2.3. AVERAGE SELLING PRICE (USD)
10.3.1.3. CUPS
10.3.1.3.1. MARKET VALUE (USD MILLION)
10.3.1.3.2. MARKET VOLUME (UNITS)
10.3.1.3.3. AVERAGE SELLING PRICE (USD)
10.3.1.4. OTHERS
10.3.2 ASSAY KITS
10.3.2.1. ENZYME IMMUNOASSAY (EIA) KITS
10.3.2.1.1. MARKET VALUE (USD MILLION)
10.3.2.1.2. MARKET VOLUME (UNITS)
10.3.2.1.3. AVERAGE SELLING PRICE (USD)
10.3.2.2. FLUORESCENCE IMMUNOASSAY (FIA) KITS
10.3.2.2.1. MARKET VALUE (USD MILLION)
10.3.2.2.2. MARKET VOLUME (UNITS)
10.3.2.2.3. AVERAGE SELLING PRICE (USD)
10.3.2.3. CHEMILUMINESCENCE IMMUNOASSAY (CLIA) KITS
10.3.2.3.1. MARKET VALUE (USD MILLION)
10.3.2.3.2. MARKET VOLUME (UNITS)
10.3.2.3.3. AVERAGE SELLING PRICE (USD)
10.3.2.4. RAPID LATERAL FLOW IMMUNOASSAY (LFIA) KITS
10.3.2.4.1. MARKET VALUE (USD MILLION)
10.3.2.4.2. MARKET VOLUME (UNITS)
10.3.2.4.3. AVERAGE SELLING PRICE (USD)
10.3.2.5. RADIOIMMUNOASSAY (RIA) KITS
10.3.2.5.1. MARKET VALUE (USD MILLION)
10.3.2.5.2. MARKET VOLUME (UNITS)
10.3.2.5.3. AVERAGE SELLING PRICE (USD)
10.4 REAGENTS
10.5 OTHERS
11 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , BY SAMPLE TYPE
11.1 OVERVIEW
11.2 URINE
11.3 SALIVA
11.4 HAIR
11.5 BREATH
11.6 OTHERS
12 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , BY MODE
12.1 OVERVIEW
12.2 POINT OF CARE TESTING
12.3 LABORATORY BASED TESTING
13 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , BY APPLICATION
13.1 OVERVIEW
13.2 MEDICAL SCREENING
13.3 PAIN MANAGEMENT
13.4 LAW ENFORCEMENT AND CRIMINAL JUSTICE
13.5 WORKPLACE SCREENING
13.6 SUBSTANCE ABUSE TREATMENT AND REHABILITATION
13.7 DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS
13.8 PARENTAL OR HOME DRUG TESTING
13.9 SPORTS AND ATHLETICS TESTINGS
13.1 OTHERS
14 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , BY DRUG TYPE
14.1 OVERVIEW
14.2 ALCOHOL
14.3 COCAINE
14.4 MARIJUANA/ CANNABIS
14.5 LYSERGIC ACID DIETHYLAMIDE
14.6 OPIOIDS
14.7 OTHERS
15 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 LABORATORIES
15.4 WORKPLACE
15.5 AT HOME
15.6 OTHERS
16 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDERS
16.3 RETAIL SALES
16.4 ONLINE
16.5 OTHERS
17 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , SWOT AND DBMR ANALYSIS
18 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , BY REGION
19.1 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.2 NORTH AMERICA
19.2.1 U.S.
19.2.2 CANADA
19.2.3 MEXICO
19.3 EUROPE
19.3.1 GERMANY
19.3.2 U.K.
19.3.3 ITALY
19.3.4 FRANCE
19.3.5 SPAIN
19.3.6 RUSSIA
19.3.7 SWITZERLAND
19.3.8 TURKEY
19.3.9 BELGIUM
19.3.10 NETHERLANDS
19.3.11 DENMARK
19.3.12 SWEDEN
19.3.13 POLAND
19.3.14 NORWAY
19.3.15 FINLAND
19.3.16 REST OF EUROPE
19.4 ASIA-PACIFIC
19.4.1 JAPAN
19.4.2 CHINA
19.4.3 SOUTH KOREA
19.4.4 INDIA
19.4.5 SINGAPORE
19.4.6 THAILAND
19.4.7 INDONESIA
19.4.8 MALAYSIA
19.4.9 PHILIPPINES
19.4.10 AUSTRALIA
19.4.11 NEW ZEALAND
19.4.12 VIETNAM
19.4.13 TAIWAN
19.4.14 REST OF ASIA-PACIFIC
19.5 SOUTH AMERICA
19.5.1 BRAZIL
19.5.2 ARGENTINA
19.5.3 REST OF SOUTH AMERICA
19.6 MIDDLE EAST AND AFRICA
19.6.1 SOUTH AFRICA
19.6.2 EGYPT
19.6.3 BAHRAIN
19.6.4 UNITED ARAB EMIRATES
19.6.5 KUWAIT
19.6.6 OMAN
19.6.7 QATAR
19.6.8 SAUDI ARABIA
19.6.9 REST OF MEA
19.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
20 GLOBAL DRUGS OF ABUSE (DOA) TESTING MARKET , COMPANY PROFILE
20.1 EPPENDORF SE
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 THERMO FISHER SCIENTIFIC INC.
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 BECKMAN COULTER, INC.
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 BMG LABTECH
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 DRÄGERWERK AG & CO. KGAA
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 LIFELOC TECHNOLOGIES, INC
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPMENTS
20.7 INTOXIMETERS
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPMENTS
20.8 CMI INC.
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPMENTS
20.9 ABBOTT
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPMENTS
20.1 ALERE.
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPMENTS
20.11 BIO-RAD LABORATORIES, INC.
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPMENTS
20.12 SIEMENS HEALTHCARE PRIVATE LIMITED
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPMENTS
20.13 F. HOFFMANN-LA ROCHE LTD
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPMENTS
20.14 AK GLOBALTECH CORPORATION
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPMENTS
20.15 C4 DEVELOPMENT LTD
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPMENTS
20.16 BACTRACK
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPMENTS
20.17 LION LABORATORIES LIMITED
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPMENTS
20.18 SECURETEC
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPMENTS
20.19 CONTRALCO
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPMENTS
20.2 ALCOHOL COUNTERMEASURE SYSTEMS CORP
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPMENTS
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
